Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 17, 2021 16:01 ET | Source: Passage Bio

Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
September 07, 2021 07:00 ET | Source: Passage Bio

Passage Bio Announces Maxine Gowen, Ph.D., as Chairwoman of the Board of Directors

PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
September 02, 2021 07:00 ET | Source: Passage Bio

Passage Bio to Present at Citi 16th Annual BioPharma Virtual Conference

PHILADELPHIA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
August 27, 2021 16:01 ET | Source: Passage Bio

Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
August 05, 2021 07:00 ET | Source: Passage Bio

Passage Bio Reports Second Quarter 2021 Financial Results and Provides Recent Business Highlights

Expanded strategic collaboration with University of Pennsylvania’s Gene Therapy Program to advance genetic medicines for large CNS diseases, initially focused on Alzheimer’s Disease and Temporal Lobe...
August 04, 2021 21:00 ET | Source: Passage Bio

Passage Bio Mourns the Sudden Passing of Chairman of the Board Tadataka Yamada, M.D.

PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
August 04, 2021 07:00 ET | Source: Passage Bio

Passage Bio to Present at 12th Annual Wedbush PacGrow Healthcare Conference

PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic...
July 29, 2021 07:00 ET | Source: Passage Bio

Passage Bio to Report Second Quarter 2021 Financial Results on August 5, 2021

PHILADELPHIA, July 29, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic...
July 21, 2021 07:00 ET | Source: Passage Bio

Passage Bio Announces Inducement Award for Newly Appointed Chief Commercial Officer Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, July 21, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic...
July 19, 2021 07:00 ET | Source: Passage Bio

Passage Bio Announces Key Executive Appointments

PHILADELPHIA, July 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right